Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.

  title={Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.},
  author={Susan E Conway and Andrew Y Hwang and Charles D Ponte and John Gums},
  volume={37 2},
The direct acting oral anticoagulants (DOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic properties and equal or superior efficacy and an improved safety profile compared with warfarin. Noted shortcomings with DOACs are shorter half-lives requiring stricter adherence, lack of standardized laboratory monitoring, lack of anticoagulation reversal agents, and loss of routine coagulation monitoring leading to fewer patient-clinician… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 31 times. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 57 references

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology • 2015
View 10 Excerpts
Highly Influenced

Laboratory monitoring of the non-vitamin K oral anticoagulants.

Journal of the American College of Cardiology • 2014
View 9 Excerpts
Highly Influenced

Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2012
View 11 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…